NMDA receptor antagonists play a crucial role in Alzheimer's disease and dementia by modulating glutamate activity in the brain. Glutamate, an excitatory neurotransmitter, is implicated in neurodegenerative processes when present in excess. NMDA receptor antagonists, such as memantine, work by blocking these receptors, thereby regulating glutamate levels and reducing neuronal damage associated with Alzheimer's disease progression. This class of drugs helps improve cognitive function and delay symptom progression by maintaining neurotransmitter balance. Unlike other treatments, NMDA receptor antagonists target specific mechanisms of neurodegeneration, offering a unique therapeutic approach in managing Alzheimer's disease and related dementias. Ongoing research continues to explore their efficacy and potential in providing symptomatic relief and possibly altering disease progression in affected individuals.
Title : Cerebral vascular calcium signaling in diabetic alzheimer's disease-related dementias
Yong Xiao Wang, Albany Medical College, United States
Title : Deep learning-based risk assessment of cognitive impairment using health examination data
Kaoru Sakatani, The University of Tokyo, Japan
Title : Evaluation of the neuroprotective potential of indicaxanthin from opuntia ficus indica fruit against dysmetabolism-related neurodegeneration both in vivo and in vitro
Mario Allegra, University of Palermo, Italy
Title : Cogs Club: Making a difference
Jacqueline Tuppen, Cogs Club, United Kingdom
Title : Development of imaging based biomarkers for neurovascular abnormalities in neurodegenerative diseases
Jun Hua, Johns Hopkins University School of Medicine, United States
Title : Psychosocial considerations in management of corticobasal degeneration
Esraa Askar, Forest Hills Hospital, United States